A second genome,
a thousand times older
than us.
The human microbiome is the community of ~38 trillion microorganisms — bacteria, fungi, archaea — that live with us and on us. It outweighs our brain. It encodes one hundred and fifty times more genes than our own DNA.
For most of medical history, we ignored it. The last twenty years of sequencing changed that — we now know the microbiome influences immunity, inflammation, metabolism, mood and skin.
Medalta works on the practical end of that science: turning what we know about specific strains and metabolites into formulations that can sit on a pharmacy shelf, with claims a clinician can defend.
From strain library to shelf.
A four-stage development pipeline shared across every Medalta product line.
We start with our reference library of 120+ characterised strains, narrowing to candidates by mechanism, stability and clinical history.
Our formulation team combines selected strains with stabilisers, prebiotics and delivery systems optimised for target site, shelf life and regulatory pathway.
Every Medalta product undergoes clinical evaluation — from in-vitro mechanism studies to human efficacy trials — ensuring claims are evidence-based and defensible.
Production follows pharmaceutical-grade GMP protocols with end-to-end traceability, potency verification and stability testing at certified European facilities.
Clinically studied,
transparently sourced.
01
Lactobacillus rhamnosus GG
Characterised bacterial strains in our reference library
02
Bifidobacterium longum
Selected for its anti-inflammatory profile and IBS evidence base.
03
Postbiotic ω-stabiliser
A proprietary postbiotic active developed for the Inflomega programme.
04
Lactobacillus crispatus M3
Vaginal-microbiome-derived strain for Urobiotic. Limited to clinical-grade markets.
Build a microbiome programme with us.
Medalta partners with distributors, clinics and brands on white-label microbiome lines, regional registration and clinical co-development.
